A series of pyrazoloquinolines, possessing (hetero) arylhydroxymethyl substituents at the quinoline C-4 position were evaluated as PDE10A inhibitors. Among these, methylpyrimidyl analogue 15 was identified as having good rodent and monkey exposure, and a MED of 10mg/kg in an in vivo model.